Trial Profile
A multinational, randomized, double-blind, parallel group comparative trial on the effects of 2 years treatment with tibolone (1.25 mg Org OD 14) and raloxifene (60 mg) on bone mineral density in osteopenic postmenopausal women
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Feb 2022
Price :
$35
*
At a glance
- Drugs Tibolone (Primary) ; Raloxifene
- Indications Bone resorption; Metabolic bone diseases; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms STEP
- Sponsors Merck Sharp & Dohme; Organon
- 06 Oct 2009 Additional lead trial centre and sponsor (Schering-Plough) identified as reported by ClinicalTrials.gov.
- 01 Aug 2008 Results have been published in Osteoporosis International.
- 09 Mar 2007 New trial record.